Carlo Caltagirone

Carlo Caltagirone is an expert in Neurology at Fondazione Santa Lucia (Italy). As of September 2026, ScienceLeadR ranks Carlo Caltagirone in the top 1% of experts worldwide for Cognition Disorders and Cognitive Dysfunction. Carlo Caltagirone has authored 1,027 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 1 of them ongoing. SLR score: 2,643 (community average: 125). How the SLR is computed.

Neurology

Subspecialties: Psychology - Genetics - Psychiatry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on September 3, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1985 - 2026

Source: PubMed

Fondazione Santa Lucia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1027

Citations

Citations: 53 932 1st author: 26 Last author: 231 Unique author: 0

Main journals

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
Stage-dependent effects of cognitive reserve on memory and brain structural integrity across the spectrum from healthy aging to Alzheimer's disease. PMID 42528828 — alzheimer disease, aging, brain, cognitive dysfunction, cognitive reserve, healthy aging, memory	Front Hum Neurosci	2026
Expanding the Clinical and Mutational Spectrum of FBXO7-Related Parkinsonism: A Novel Italian Family and Comprehensive Literature Review. PMID 42510804 — genes, genomics, parkinsonian disorders, phenotype, cognitive dysfunction, signs and symptoms	Genes (Basel)	2026
Are MMSE and ACE-R useful for detecting the earliest stages of Alzheimer's disease? A comparative study. PMID 42479744 — alzheimer disease, cognitive dysfunction, cognition disorders	J Neuropsychol	2026
Hippocampal-cortical structural networks in the progression of cognitive impairment: A source-based morphometry analysis in individuals with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease. PMID 42392003 — alzheimer disease, aging, cognitive dysfunction, cognition disorders, neurophysiology, memory, memory, episodic	Neurobiol Aging	2026
Shaping the cognitive reserve: the role of lifelong enrichment and education in the Alzheimer's disease continuum. PMID 42221031 — exercise, alzheimer disease, cognitive dysfunction, cognitive reserve, education, memory, cognition	Front Aging Neurosci	2026

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 5

Phase 2 1

Phase 3 1

By status:

Completed 6

Recruiting 1

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 5

multicentric2to4 1

multicentric5to9 0

multicentricup10 1

Main Topics

Nervous System Diseases 5

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
A research study to compare the antidepressant ability and safety of Samyr tablets versus placebo tablets as an adjunct to additional antidepressant treatment in patients with major depressive disorder (MDD) 2024-513019-29-00 — depression, antidepressive agents, safety, multiple chronic conditions, tablets, signs and symptoms, depressive disorder, research, therapeutics, depressive disorder, major	Phase 3	Recruiting	2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice